TESARO Stock Price, News & Analysis (NASDAQ:TSRO)

$81.44 -0.58 (-0.71 %)
(As of 12/12/2017 04:00 PM ET)
Previous Close$82.02
Today's Range$81.02 - $82.90
52-Week Range$79.03 - $192.94
Volume388,736 shs
Average Volume1.01 million shs
Market Capitalization$4.59 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.52

About TESARO (NASDAQ:TSRO)

TESARO logoTESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.

Receive TSRO News and Ratings via Email

Sign-up to receive the latest news and ratings for TSRO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:TSRO
CUSIP88156910
Phone339-970-0900

Debt

Debt-to-Equity Ratio0.34%
Current Ratio4.73%
Quick Ratio4.35%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$44.82 million
Price / Sales98.81
Cash FlowN/A
Price / CashN/A
Book Value$11.44 per share
Price / Book7.12

Profitability

Trailing EPS($8.44)
Net Income$-387,470,000.00
Net Margins-251.22%
Return on Equity-93.39%
Return on Assets-61.53%

Miscellaneous

Employees446
Outstanding Shares54,380,000

TESARO (NASDAQ:TSRO) Frequently Asked Questions

What is TESARO's stock symbol?

TESARO trades on the NASDAQ under the ticker symbol "TSRO."

How were TESARO's earnings last quarter?

TESARO Inc (NASDAQ:TSRO) announced its quarterly earnings data on Tuesday, November, 7th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($1.16) by $0.69. The biopharmaceutical company earned $142.77 million during the quarter, compared to analyst estimates of $130.57 million. TESARO had a negative net margin of 251.22% and a negative return on equity of 93.39%. The firm's revenue for the quarter was up 740.3% compared to the same quarter last year. During the same period last year, the business earned ($1.72) EPS. View TESARO's Earnings History.

When will TESARO make its next earnings announcement?

TESARO is scheduled to release their next quarterly earnings announcement on Monday, February, 26th 2018. View Earnings Estimates for TESARO.

Where is TESARO's stock going? Where will TESARO's stock price be in 2017?

23 Wall Street analysts have issued 12 month price targets for TESARO's stock. Their forecasts range from $117.00 to $236.00. On average, they anticipate TESARO's stock price to reach $158.57 in the next twelve months. View Analyst Ratings for TESARO.

What are Wall Street analysts saying about TESARO stock?

Here are some recent quotes from research analysts about TESARO stock:

  • 1. According to Zacks Investment Research, "Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Company's product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer and other cancer indications, and Niraparib, an orally active and potent poly (ADP-ribose) polymerase inhibitor for the treatment of patients with solid tumors. Tesaro, Inc. is based in Waltham, Massachusetts. " (11/8/2017)
  • 2. Cann analysts commented, "Total Q3 revenue of $142.8 million included a $100 million upfront payment. Net of the upfront payment, revenue was 27.4% higher than our estimated $33.6 million due to stronger than estimated Zejula sales. Total operating expenses of $164.9 million were 3.0% lower than our estimated $170.0 million due to lower than estimated R&D expense. Due to the combination of higher than estimated revenue and slightly lower expenses, Tesaro lost $0.47 per share compared to our estimated loss per share of $2.56." (11/7/2017)
  • 3. FBR & Co analysts commented, "We received our first data snapshot from the RX-3117 Phase 2a study in advanced muscle invasive bladder cancer at ASCO this weekend with data coming from 10 patients in stage 1 of the study. The study achieved the predefined efficacy criteria (two of ten patients achieving a PFS of at least four months or a partial or complete tumor response), where 22% of patients have experienced PFS for a minimum of six months. One of the two aforementioned patients is still on study, achieving 175 days of stable disease. While only stage 1 of this study, we believe it is important to point out that patients who have reached this stage of disease are usually limited to palliative or best supportive care." (6/5/2017)
  • 4. Cowen Inc analysts commented, "TSRO reported 1Q financials, provided a pipeline update and commented on Zejula’s." (5/11/2017)
  • 5. Wedbush analysts commented, "With first-mover advantage in the maintenance setting, a lack of requirement for a diagnostic, as well clinical data that is at least as good as Lynparza in gBRCA patients, we continue to believe that TSRO remains an attractive acquisition candidate." (3/28/2017)

Who are some of TESARO's key competitors?

Who are TESARO's key executives?

TESARO's management team includes the folowing people:

  • David M. Mott, Independent Chairman of the Board (Age 51)
  • Mary Lynne Hedley Ph.D., President, Chief Operating Officer, Director (Age 54)
  • Leon O. Moulder Jr., Chief Executive Officer, Director (Age 59)
  • Timothy R. Pearson, Chief Financial Officer, Executive Vice President, Principal Accounting Officer (Age 49)
  • Jeffrey H. Hanke Ph.D., Executive Vice President - Research and Development, Chief Scientific Officer (Age 59)
  • Joseph L. Farmer, Senior Vice President, General Counsel, Secretary (Age 45)
  • Grant C. Bogle, Senior Vice President, Chief Commercial Officer (Age 59)
  • Martin H. Huber M.D., Senior Vice President and Chief Medical Officer (Age 57)
  • Lawrence M. Alleva, Independent Director (Age 67)
  • James O. Armitage M.D., Independent Director (Age 70)

Who owns TESARO stock?

TESARO's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Janus Henderson Group PLC (1.65%), Pictet Asset Management Ltd. (1.16%), Bank of New York Mellon Corp (1.05%), Alyeska Investment Group L.P. (0.75%), Perceptive Advisors LLC (0.71%) and Jennison Associates LLC (0.62%). Company insiders that own TESARO stock include Arnold L Oronsky, Edward C English, Enterprise Associates 13 L New, Grant C Bogle, James O Armitage, Jeffrey H Hanke, Martin H Jr Huber, Mary Lynne Hedley and Orlando Oliveira. View Institutional Ownership Trends for TESARO.

Who sold TESARO stock? Who is selling TESARO stock?

TESARO's stock was sold by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Bank of New York Mellon Corp, Macquarie Group Ltd., Schwab Charles Investment Management Inc., C WorldWide Group Holding A S, First Trust Advisors LP, TD Asset Management Inc. and State of Wisconsin Investment Board. Company insiders that have sold TESARO company stock in the last year include Edward C English, Grant C Bogle, James O Armitage, Martin H Jr Huber, Mary Lynne Hedley and Orlando Oliveira. View Insider Buying and Selling for TESARO.

Who bought TESARO stock? Who is buying TESARO stock?

TESARO's stock was bought by a variety of institutional investors in the last quarter, including TimesSquare Capital Management LLC, Pictet Asset Management Ltd., Janus Henderson Group PLC, Sectoral Asset Management Inc, Artisan Partners Limited Partnership, Candriam Luxembourg S.C.A., Alyeska Investment Group L.P. and AXA. Company insiders that have bought TESARO stock in the last two years include Arnold L Oronsky and Enterprise Associates 13 L New. View Insider Buying and Selling for TESARO.

How do I buy TESARO stock?

Shares of TESARO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TESARO's stock price today?

One share of TESARO stock can currently be purchased for approximately $81.44.

How big of a company is TESARO?

TESARO has a market capitalization of $4.59 billion and generates $44.82 million in revenue each year. The biopharmaceutical company earns $-387,470,000.00 in net income (profit) each year or ($8.44) on an earnings per share basis. TESARO employs 446 workers across the globe.

How can I contact TESARO?

TESARO's mailing address is 1000 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 339-970-0900.


MarketBeat Community Rating for TESARO (TSRO)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  436 (Vote Outperform)
Underperform Votes:  249 (Vote Underperform)
Total Votes:  685
MarketBeat's community ratings are surveys of what our community members think about TESARO and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

TESARO (NASDAQ:TSRO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.602.562.652.62
Ratings Breakdown: 0 Sell Rating(s)
10 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
11 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $155.88$158.21$171.32$174.11
Price Target Upside: 91.21% upside73.68% upside44.35% upside22.03% upside

TESARO (NASDAQ:TSRO) Consensus Price Target History

Price Target History for TESARO (NASDAQ:TSRO)

TESARO (NASDAQ:TSRO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/28/2017ArgusSet Price TargetBuy$154.00LowView Rating Details
11/20/2017HC WainwrightReiterated RatingBuy$158.00N/AView Rating Details
11/15/2017Leerink SwannUpgradeMarket Perform -> OutperformN/AView Rating Details
11/10/2017SunTrust BanksReiterated RatingBuy$160.00N/AView Rating Details
11/10/2017Robert W. BairdReiterated RatingHold$120.00N/AView Rating Details
11/9/2017Lake Street CapitalReiterated RatingBuy$143.00N/AView Rating Details
11/8/2017Morgan StanleyReiterated RatingOverweight$181.00 -> $165.00N/AView Rating Details
11/7/2017CannReiterated RatingBuy$199.00N/AView Rating Details
11/3/2017Jefferies GroupReiterated RatingHold$124.00N/AView Rating Details
10/23/2017Piper Jaffray CompaniesReiterated RatingNeutral -> Neutral$117.00N/AView Rating Details
10/23/2017BarclaysInitiated CoverageEqual Weight -> Equal Weight$135.00N/AView Rating Details
9/14/2017Royal Bank of CanadaInitiated CoverageSector Perform$120.00MediumView Rating Details
9/11/2017WedbushReiterated RatingOutperform$160.00LowView Rating Details
9/10/2017OppenheimerReiterated RatingBuy$199.00LowView Rating Details
9/11/2017CitigroupReiterated RatingBuy$216.00LowView Rating Details
8/20/2017Wells Fargo & CompanyReiterated RatingOutperformHighView Rating Details
8/18/2017Credit Suisse GroupSet Price TargetBuy$198.00 -> $190.00HighView Rating Details
8/16/2017Evercore ISIInitiated CoverageIn -> In-Line$121.00HighView Rating Details
7/14/2017Janney Montgomery ScottReiterated RatingNeutralLowView Rating Details
7/7/2017GabelliInitiated CoverageBuy$175.00HighView Rating Details
6/20/2017Raymond James FinancialReiterated RatingMarket PerformMediumView Rating Details
6/20/2017Bank of AmericaReiterated RatingBuy$154.00HighView Rating Details
6/19/2017CowenLower Price TargetMarket Perform$145.00 -> $124.00HighView Rating Details
6/5/2017FBR & CoLower Price TargetMkt Perform -> Mkt Perform$200.00 -> $195.00HighView Rating Details
8/5/2016MizuhoLower Price TargetBuy$100.00 -> $94.00N/AView Rating Details
(Data available from 12/12/2015 forward)

Earnings

TESARO (NASDAQ:TSRO) Earnings History and Estimates Chart

Earnings by Quarter for TESARO (NASDAQ:TSRO)

TESARO (NASDAQ TSRO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018($2.35)N/AView Earnings Details
11/7/2017Q3 2017($1.16)($0.47)$130.57 million$142.77 millionViewN/AView Earnings Details
8/8/2017Q2 2017($2.52)($2.82)$18.61 million$29.50 millionViewListenView Earnings Details
5/9/2017Q1 2017($2.26)($2.55)$3.84 million$3.10 millionViewListenView Earnings Details
11/3/2016Q3($1.92)($1.98)$4.39 million$3.73 millionViewN/AView Earnings Details
5/5/2016Q1($1.69)($2.22)$2.48 million$0.31 millionViewN/AView Earnings Details
2/25/2016Q4($1.63)($1.89)$3.45 million$0.23 millionViewListenView Earnings Details
10/29/2015Q315($1.52)($1.66)$0.09 millionViewListenView Earnings Details
8/6/2015Q215($1.14)($1.51)ViewListenView Earnings Details
4/30/2015Q115($1.12)($1.30)ViewListenView Earnings Details
2/19/2015Q414($1.03)($1.33)ViewListenView Earnings Details
11/5/2014Q314($1.04)($1.01)ViewN/AView Earnings Details
7/24/2014Q214($0.87)($1.03)ViewN/AView Earnings Details
4/30/2014Q114($1.06)($1.43)ViewN/AView Earnings Details
2/19/2014Q413($0.78)($0.72)ViewN/AView Earnings Details
11/7/2013Q313($0.69)($0.88)ViewN/AView Earnings Details
7/25/2013Q2 2013($0.63)($0.67)ViewN/AView Earnings Details
4/25/2013Q1 2013($0.62)($0.66)ViewN/AView Earnings Details
2/14/2013Q4 2012($0.65)($15.41)ViewN/AView Earnings Details
10/25/2012($0.55)($0.52)ViewN/AView Earnings Details
7/26/2012($0.55)($4.11)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

TESARO (NASDAQ:TSRO) Earnings Estimates

2017 EPS Consensus Estimate: ($8.70)
2018 EPS Consensus Estimate: ($6.49)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20175($2.39)($1.98)($2.20)
Q2 20176($3.10)($2.15)($2.59)
Q3 20176($2.57)($0.52)($1.50)
Q4 20176($2.79)($1.86)($2.41)
Q1 20184($2.17)($1.35)($1.90)
Q2 20184($1.94)($0.93)($1.61)
Q3 20184($1.94)($0.94)($1.56)
Q4 20184($1.76)($1.16)($1.43)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for TESARO (NASDAQ:TSRO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

TESARO (NASDAQ TSRO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 34.60%
Insider Trades by Quarter for TESARO (NASDAQ:TSRO)
Institutional Ownership by Quarter for TESARO (NASDAQ:TSRO)

TESARO (NASDAQ TSRO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/4/2017Martin H Jr. HuberSVPSell829$85.24$70,663.96View SEC Filing  
9/22/2017Martin H Jr. HuberSVPSell592$118.60$70,211.20View SEC Filing  
9/18/2017James O ArmitageDirectorSell10,000$117.13$1,171,300.00View SEC Filing  
9/6/2017Edward C EnglishVPSell10,862$134.92$1,465,501.04View SEC Filing  
9/5/2017Orlando OliveiraSVPSell71$132.66$9,418.86View SEC Filing  
9/1/2017Grant C. BogleVPSell14,167$135.00$1,912,545.00View SEC Filing  
6/6/2017Edward C EnglishVPSell8,500$138.65$1,178,525.00View SEC Filing  
4/3/2017Martin H Jr. HuberSVPSell829$153.02$126,853.58View SEC Filing  
3/6/2017Edward C EnglishVPSell10,000$178.06$1,780,600.00View SEC Filing  
3/2/2017Edward C EnglishVPSell229$177.61$40,672.69View SEC Filing  
3/2/2017Grant C. BogleSVPSell1,447$177.61$257,001.67View SEC Filing  
3/2/2017Mary Lynne HedleyCOOSell3,927$177.61$697,474.47View SEC Filing  
1/3/2017Martin H. Jr. HuberSVPSell190$136.26$25,889.40View SEC Filing  
11/2/2016Martin H Jr. HuberSVPSell327$121.29$39,661.83View SEC Filing  
9/22/2016Martin H Jr. HuberSVPSell408$108.12$44,112.96View SEC Filing  
9/8/2016Edward C EnglishVPSell7,000$88.54$619,780.00View SEC Filing  
8/30/2016Jeffrey H HankeVPSell29,166$86.04$2,509,442.64View SEC Filing  
6/30/2016Jeffrey H HankeVPSell12,500$74.35$929,375.00View SEC Filing  
6/10/2016Edward C EnglishVPSell7,000$40.75$285,250.00View SEC Filing  
3/18/2016Arnold L OronskyDirectorBuy142,085$35.19$4,999,971.15View SEC Filing  
3/18/2016Enterprise Associates 13 L NewMajor ShareholderBuy710,429$35.19$24,999,996.51View SEC Filing  
3/10/2016Edward C EnglishVPSell7,000$43.71$305,970.00View SEC Filing  
12/10/2015Edward C. EnglishVPSell17,000$50.19$853,230.00View SEC Filing  
9/8/2015James O ArmitageDirectorBuy500$54.63$27,315.00View SEC Filing  
12/12/2014James O ArmitageDirectorBuy1,000$38.16$38,160.00View SEC Filing  
9/29/2014Lawrence M AllevaDirectorBuy1,100$26.17$28,787.00View SEC Filing  
7/31/2013Lawrence M AllevaDirectorBuy1,449$34.33$49,744.17View SEC Filing  
6/5/2013Peter J BarrisMajor ShareholderSell3,583$39.00$139,737.00View SEC Filing  
4/30/2013Lawrence M AllevaDirectorBuy1,050$28.10$29,505.00View SEC Filing  
11/1/2012Lawrence M AllevaDirectorBuy3,240$15.45$50,058.00View SEC Filing  
8/30/2012Leon O Moulder JrCEOBuy10,000$11.69$116,900.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

TESARO (NASDAQ TSRO) News Headlines

Source:
DateHeadline
TESARO (TSRO) versus Its Peers Head to Head SurveyTESARO (TSRO) versus Its Peers Head to Head Survey
www.americanbankingnews.com - December 12 at 5:16 PM
TESARO Inc (TSRO) Given Consensus Recommendation of "Buy" by AnalystsTESARO Inc (TSRO) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - December 8 at 9:38 PM
TESARO (TSRO) versus Its Rivals Head to Head AnalysisTESARO (TSRO) versus Its Rivals Head to Head Analysis
www.americanbankingnews.com - December 8 at 9:36 AM
Insider Selling: TESARO Inc (TSRO) SVP Sells 829 Shares of StockInsider Selling: TESARO Inc (TSRO) SVP Sells 829 Shares of Stock
www.americanbankingnews.com - December 5 at 9:52 PM
ETFs with exposure to TESARO, Inc. : December 5, 2017ETFs with exposure to TESARO, Inc. : December 5, 2017
finance.yahoo.com - December 5 at 3:26 PM
Contrasting TESARO (TSRO) & Its RivalsContrasting TESARO (TSRO) & Its Rivals
www.americanbankingnews.com - December 2 at 7:18 PM
Tesaro Becomes Oversold (TSRO) - NasdaqTesaro Becomes Oversold (TSRO) - Nasdaq
www.nasdaq.com - December 1 at 3:30 PM
Market Trends Toward New Normal in Infinity Pharmaceuticals, Edison International, Anthem, TESARO, Brunswick, and BroadSoft — Emerging Consolidated Expectations, Analyst RatingsMarket Trends Toward New Normal in Infinity Pharmaceuticals, Edison International, Anthem, TESARO, Brunswick, and BroadSoft — Emerging Consolidated Expectations, Analyst Ratings
finance.yahoo.com - December 1 at 11:22 AM
Critical Contrast: TESARO (TSRO) versus The CompetitionCritical Contrast: TESARO (TSRO) versus The Competition
www.americanbankingnews.com - November 30 at 9:30 AM
$52.32 Million in Sales Expected for TESARO Inc (TSRO) This Quarter$52.32 Million in Sales Expected for TESARO Inc (TSRO) This Quarter
www.americanbankingnews.com - November 29 at 2:08 AM
TESARO (TSRO) Given a $154.00 Price Target at ArgusTESARO (TSRO) Given a $154.00 Price Target at Argus
www.americanbankingnews.com - November 28 at 9:12 AM
TESARO Announces Availability of VARUBI® (rolapitant) IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy in the United StatesTESARO Announces Availability of VARUBI® (rolapitant) IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy in the United States
finance.yahoo.com - November 28 at 8:21 AM
 Brokerages Anticipate TESARO Inc (TSRO) Will Announce Earnings of -$2.37 Per Share Brokerages Anticipate TESARO Inc (TSRO) Will Announce Earnings of -$2.37 Per Share
www.americanbankingnews.com - November 27 at 11:20 PM
ETFs with exposure to TESARO, Inc. : November 24, 2017ETFs with exposure to TESARO, Inc. : November 24, 2017
finance.yahoo.com - November 24 at 6:22 PM
TESARO (TSRO) Ovarian Cancer Drug Zejula Gets Approval in EU - NasdaqTESARO (TSRO) Ovarian Cancer Drug Zejula Gets Approval in EU - Nasdaq
www.nasdaq.com - November 22 at 6:18 PM
TESARO Announces Participation in Two Investor Conferences - GlobeNewswire (press release)TESARO Announces Participation in Two Investor Conferences - GlobeNewswire (press release)
globenewswire.com - November 22 at 6:17 PM
TESARO Announces Participation in Two Investor ConferencesTESARO Announces Participation in Two Investor Conferences
finance.yahoo.com - November 22 at 6:17 PM
TESARO, Inc. (TSRO) Stock Rating Reaffirmed by HC WainwrightTESARO, Inc. (TSRO) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - November 20 at 12:04 PM
TESARO (TSRO) Announce EC Approval of ZEJULA to Treat Ovarian CancerTESARO (TSRO) Announce EC Approval of ZEJULA to Treat Ovarian Cancer
www.streetinsider.com - November 20 at 11:32 AM
TESARO, Inc. (TSRO) Upgraded to Outperform at Leerink SwannTESARO, Inc. (TSRO) Upgraded to Outperform at Leerink Swann
www.americanbankingnews.com - November 19 at 5:38 PM
TESARO, Inc. to Post FY2017 Earnings of ($8.61) Per Share, Leerink Swann Forecasts (TSRO)TESARO, Inc. to Post FY2017 Earnings of ($8.61) Per Share, Leerink Swann Forecasts (TSRO)
www.americanbankingnews.com - November 17 at 7:12 PM
Tesaro Stock Could Have 41% UpsideTesaro Stock Could Have 41% Upside
finance.yahoo.com - November 15 at 5:31 PM
ETFs with exposure to TESARO, Inc. : November 13, 2017ETFs with exposure to TESARO, Inc. : November 13, 2017
finance.yahoo.com - November 14 at 12:09 PM
TESARO, Inc. (TSRO) Receives Consensus Rating of "Hold" from BrokeragesTESARO, Inc. (TSRO) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 13 at 9:34 PM
Equities Analysts Issue Forecasts for TESARO, Inc.s FY2017 Earnings (TSRO)Equities Analysts Issue Forecasts for TESARO, Inc.'s FY2017 Earnings (TSRO)
www.americanbankingnews.com - November 13 at 1:48 AM
TESARO, Inc. (TSRO) Earns Buy Rating from SunTrust Banks, Inc.TESARO, Inc. (TSRO) Earns Buy Rating from SunTrust Banks, Inc.
www.americanbankingnews.com - November 11 at 4:56 PM
TESAROs (TSRO) "Hold" Rating Reaffirmed at Robert W. BairdTESARO's (TSRO) "Hold" Rating Reaffirmed at Robert W. Baird
www.americanbankingnews.com - November 11 at 12:10 PM
FY2017 EPS Estimates for TESARO, Inc. (TSRO) Raised by AnalystFY2017 EPS Estimates for TESARO, Inc. (TSRO) Raised by Analyst
www.americanbankingnews.com - November 10 at 12:41 PM
Gabelli Weighs in on TESARO, Inc.s FY2017 Earnings (TSRO)Gabelli Weighs in on TESARO, Inc.'s FY2017 Earnings (TSRO)
www.americanbankingnews.com - November 10 at 12:40 PM
FY2017 EPS Estimates for TESARO, Inc. (TSRO) Reduced by Leerink SwannFY2017 EPS Estimates for TESARO, Inc. (TSRO) Reduced by Leerink Swann
www.americanbankingnews.com - November 10 at 12:40 PM
FY2017 EPS Estimates for TESARO, Inc. Lifted by Analyst (TSRO)FY2017 EPS Estimates for TESARO, Inc. Lifted by Analyst (TSRO)
www.americanbankingnews.com - November 10 at 12:40 PM
TESARO, Inc. (TSRO) to Post FY2017 Earnings of ($8.20) Per Share, Jefferies Group ForecastsTESARO, Inc. (TSRO) to Post FY2017 Earnings of ($8.20) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - November 10 at 12:40 PM
FY2020 Earnings Forecast for TESARO, Inc. (TSRO) Issued By Jefferies GroupFY2020 Earnings Forecast for TESARO, Inc. (TSRO) Issued By Jefferies Group
www.americanbankingnews.com - November 9 at 4:02 PM
Lake Street Capital Reaffirms "Buy" Rating for TESARO, Inc. (TSRO)Lake Street Capital Reaffirms "Buy" Rating for TESARO, Inc. (TSRO)
www.americanbankingnews.com - November 9 at 3:42 PM
FY2019 Earnings Forecast for TESARO, Inc. (TSRO) Issued By Oppenheimer HoldingsFY2019 Earnings Forecast for TESARO, Inc. (TSRO) Issued By Oppenheimer Holdings
www.americanbankingnews.com - November 9 at 3:40 PM
 Analysts Anticipate TESARO, Inc. (TSRO) Will Post Earnings of -$2.31 Per Share Analysts Anticipate TESARO, Inc. (TSRO) Will Post Earnings of -$2.31 Per Share
www.americanbankingnews.com - November 9 at 11:40 AM
TESARO, Inc. (TSRO) Forecasted to Post Q1 2018 Earnings of ($2.11) Per ShareTESARO, Inc. (TSRO) Forecasted to Post Q1 2018 Earnings of ($2.11) Per Share
www.americanbankingnews.com - November 9 at 11:12 AM
TESARO Announces Third-Quarter 2017 Operating Results - GlobeNewswire (press release)TESARO Announces Third-Quarter 2017 Operating Results - GlobeNewswire (press release)
globenewswire.com - November 9 at 8:41 AM
Earnings Reaction History: TESARO, Inc., 66.7% Follow-Through Indicator, 5.1% Sensitive - NasdaqEarnings Reaction History: TESARO, Inc., 66.7% Follow-Through Indicator, 5.1% Sensitive - Nasdaq
www.nasdaq.com - November 9 at 8:41 AM
TESARO, Inc. (TSRO) Earns Buy Rating from HC WainwrightTESARO, Inc. (TSRO) Earns Buy Rating from HC Wainwright
www.americanbankingnews.com - November 8 at 10:26 PM
TESARO, Inc. (TSRO) Releases Quarterly  Earnings Results, Beats Expectations By $0.69 EPSTESARO, Inc. (TSRO) Releases Quarterly Earnings Results, Beats Expectations By $0.69 EPS
www.americanbankingnews.com - November 8 at 3:02 PM
TESARO, Inc. (TSRO) Price Target Cut to $165.00TESARO, Inc. (TSRO) Price Target Cut to $165.00
www.americanbankingnews.com - November 8 at 11:13 AM
TESARO, Inc. (TSRO) Given Buy Rating at CannTESARO, Inc. (TSRO) Given Buy Rating at Cann
www.americanbankingnews.com - November 7 at 11:51 PM
Tesaro reports 3Q lossTesaro reports 3Q loss
finance.yahoo.com - November 7 at 8:46 PM
TESARO, Inc. (TSRO) Rating Reiterated by Jefferies Group LLCTESARO, Inc. (TSRO) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - November 5 at 4:56 PM
TESARO, Inc. (TSRO) Expected to Earn FY2021 Earnings of $14.60 Per ShareTESARO, Inc. (TSRO) Expected to Earn FY2021 Earnings of $14.60 Per Share
www.americanbankingnews.com - October 30 at 11:53 AM
OncoQuest Announces Collaboration with TESARO in Recurrent Ovarian Cancer SettingOncoQuest Announces Collaboration with TESARO in Recurrent Ovarian Cancer Setting
www.bizjournals.com - October 27 at 7:07 AM
OPKO Health (OPK) Licensee TESARO (TSRO) Granted FDA Approval of VARUBIOPKO Health (OPK) Licensee TESARO (TSRO) Granted FDA Approval of VARUBI
www.streetinsider.com - October 27 at 7:07 AM
TESARO, Inc. (TSRO) Rating Reiterated by HC WainwrightTESARO, Inc. (TSRO) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - October 26 at 5:24 PM
TESARO (TSRO) Announces FDA Approval of VARUBI for Delayed Nausea and Vomiting Associated ChemoTESARO (TSRO) Announces FDA Approval of VARUBI for Delayed Nausea and Vomiting Associated Chemo
www.streetinsider.com - October 26 at 12:50 PM

SEC Filings

TESARO (NASDAQ:TSRO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

TESARO (NASDAQ:TSRO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

TESARO (NASDAQ TSRO) Stock Chart for Tuesday, December, 12, 2017

Loading chart…

This page was last updated on 12/12/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.